Publication | Closed Access

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study

OncologyMulti-targeted AntifolateMedicinePathologyColorectal CancerPhase Ii StudyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyFirst-line Ly231514